Zacks Investment Research downgraded shares of OvaScience Inc (NASDAQ:OVAS) from a buy rating to a hold rating in a research report sent to investors on Thursday morning.

According to Zacks, “OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts. “

Separately, Oppenheimer Holdings, Inc. reissued a hold rating on shares of OvaScience in a report on Thursday, August 3rd.

Shares of OvaScience (NASDAQ:OVAS) traded up 1.08% during mid-day trading on Thursday, hitting $1.40. The company’s stock had a trading volume of 81,077 shares. The company’s market cap is $49.96 million. OvaScience has a 52-week low of $1.25 and a 52-week high of $7.54. The stock’s 50 day moving average price is $1.40 and its 200 day moving average price is $1.48.

OvaScience (NASDAQ:OVAS) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.02. The firm had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.09 million. OvaScience had a negative return on equity of 82.96% and a negative net margin of 21,650.00%. The company’s revenue was down 55.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.62) EPS. Equities analysts forecast that OvaScience will post ($1.66) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/ovascience-inc-ovas-lowered-to-hold-at-zacks-investment-research/1613874.html.

A number of institutional investors have recently made changes to their positions in the stock. Jennison Associates LLC raised its holdings in OvaScience by 0.4% in the 2nd quarter. Jennison Associates LLC now owns 2,191,258 shares of the biotechnology company’s stock worth $3,418,000 after purchasing an additional 7,731 shares during the period. Wells Fargo & Company MN raised its holdings in OvaScience by 28.8% in the 2nd quarter. Wells Fargo & Company MN now owns 164,283 shares of the biotechnology company’s stock worth $256,000 after purchasing an additional 36,720 shares during the period. Susquehanna International Group LLP raised its holdings in OvaScience by 87.2% in the 2nd quarter. Susquehanna International Group LLP now owns 112,781 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 52,538 shares during the period. UBS Asset Management Americas Inc. bought a new position in OvaScience in the 1st quarter worth $107,000. Finally, Sabby Management LLC raised its holdings in OvaScience by 20.2% in the 2nd quarter. Sabby Management LLC now owns 509,300 shares of the biotechnology company’s stock worth $795,000 after purchasing an additional 85,525 shares during the period. 56.28% of the stock is currently owned by institutional investors.

OvaScience Company Profile

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Receive News & Ratings for OvaScience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.